IL6 and plasma cell myeloma: In 2014, the anti-inflammatory activity of ABW via inhibition of the PKC-mediated JNK/NF-κB signalling pathways was reported [36]; however, the inhibitory activity of ABEA on IL-6-mediated diseases, such as inflammation, cancer cachexia, rheumatoid arthritis, hypercalcaemia, and multiple myeloma [37], through JAK2/STAT3 signal transduction has not been reported.